As of 2025-05-16, the Intrinsic Value of Oryzon Genomics SA (ORY.MC) is -0.23 EUR. This ORY.MC valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.64 EUR, the upside of Oryzon Genomics SA is -108.84%.
Based on its market price of 2.64 EUR and our intrinsic valuation, Oryzon Genomics SA (ORY.MC) is overvalued by 108.84%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.23 - -0.23 | -0.23 | -108.84% |
| P/E | (0.25) - (0.35) | (0.39) | -114.6% |
| DDM - Stable | (0.32) - (0.97) | (0.64) | -124.3% |
| DDM - Multi | (0.19) - (0.47) | (0.27) | -110.3% |
| Market Cap (mil) | 207.37 |
| Beta | 0.72 |
| Outstanding shares (mil) | 78.55 |
| Enterprise Value (mil) | 212.96 |
| Market risk premium | 7.44% |
| Cost of Equity | 11.32% |
| Cost of Debt | 5.00% |
| WACC | 10.92% |